Minerva Neurosciences, Inc. cash flow to debt ratio of -20.80K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Minerva Neurosciences, Inc.'s free cash flow has decreased 69.01K% from $-19.55M last year to $-13.51G, signaling decreasing performance

Minerva Neurosciences, Inc.'s debt to equity ratio is -0.26, signaling that the company spent its equity and risk bankruptcy.

Minerva Neurosciences, Inc. has insufficient data to evaluate this check.

Minerva Neurosciences, Inc. has negative EBITDA, making leverage ratio unreliable

Minerva Neurosciences, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Minerva Neurosciences, Inc. has insufficient data to evaluate this check.

Minerva Neurosciences, Inc.'s short-term assets of $83.10M exceed its short-term liabilities of $2.29M

Minerva Neurosciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Minerva Neurosciences, Inc.'s return on equity of 359.80%, is higher than 15.00%, indicating good performance

Minerva Neurosciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Minerva Neurosciences, Inc. had positive net income in only 1.00 out of 5 years, indicating unstable earnings

Minerva Neurosciences, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Minerva Neurosciences, Inc. has negative free cash flow, indicating cash burn

Minerva Neurosciences, Inc.'s yearly earnings has decreased -20.49K% since last year from $1.44M to $-293.42M, signaling decreasing performance

Minerva Neurosciences, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -31.13% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Minerva Neurosciences, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Minerva Neurosciences, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Minerva Neurosciences, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Minerva Neurosciences, Inc. has insufficient data to evaluate this check.

Minerva Neurosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Minerva Neurosciences, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Minerva Neurosciences, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Minerva Neurosciences, Inc. has insufficient data to evaluate this check.

Minerva Neurosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Minerva Neurosciences, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Minerva Neurosciences, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue